[Health outcomes of deprescribing proton pump inhibitors: study protocol].

Abstract

Objective: Proton pump inhibitors (PPI) are one of the groups of drugs with the highest prevalence of use. However, in many cases they are used for the treatment of unapproved indications. For this reason, in Navarra a strategy was implemented to deprescribe PPI in those cases in which their use was not indicated. Subsequently, a project was designed in order to analyze the health outcomes of that PPI deprescription strategy.

Methods: A retrospective cohort study will be developed to evaluate health outcomes obtained after the implementation of the PPI deprescription strategy. The primary outcome will be the time until a serious adverse event, defined as one that causes hospital admission or death. We will analyze whether there are differences between patients who stopped PPI treatment and those who maintained it.

Conclusions: It is expected to obtain information on the health outcomes of the proton pump inhibitor deprescription strategy and information about the convenience of continuing it.